Disease Landscape and Forecast Insights

Although motor fluctuations in Parkinson’s disease (PD) can be managed effectively in the early stages of the disease, today’s treatment paradigm is suboptimal owing to the considerable pill…

Decision Resources Group anticipates the next ten years to be an exciting time in the type 1 diabetes (T1D) space as the number of treatment options continues to grow. Existing agents fail to…

Epilepsy is a heterogeneous condition requiring individualized treatment. Neurologists consider many factors when selecting among the numerous first-, second-, and third-generation anti-epileptic (…

Inflectra (infliximab-dyyb), Pfizer/Celltrion’s Remicade biosimilar, became the first monoclonal antibody biosimilar to enter the U.S. market in late November 2016. In this series, we track…

Idiopathic pulmonary fibrosis (IPF), although a rare disease, is one of the most common interstitial lung diseases (ILDs); IPF is characterized by irreversible loss of lung function leading to high…

The regulatory and market access landscape for biosimilars is constantly evolving. For a company seeking to develop a biosimilar for multiple markets, keeping track of the similarities and…

Until recently, SCCHN treatment lacked promising late-phase agents; the only targeted therapy approved for the indication was Bristol-Myers Squibb/Eli Lilly/Merck KGaA’s Erbitux. However, the…

DRG anticipates the next ten years to be an exciting time in the hemophilia space, as the number of treatment options grow for patients with, and without, inhibitors. The hemophilia A pipeline is…

Recent and upcoming marketing authorizations and label expansions are increasing the therapy options for non-Hodgkin’s lymphoma (NHL). Despite a flourishing treatment armamentarium, tightening…

The maturing, but highly lucrative, market for multiple sclerosis (MS) disease-modifying therapies (DMTs) is becoming increasingly fragmented as attractive new options enter a powerful…

Angiogenesis inhibitors are the mainstay of the treatment of advanced renal cell carcinoma. However, the treatment algorithm is rapidly evolving driven by the approval of novel agents, including…

Idiopathic pulmonary fibrosis (IPF), although a rare disease, is one of the most common interstitial lung diseases (ILDs) and is characterized by irreversible loss of lung function leading to high…